Health
Anti-cancer drug’s mode of operation deciphered – EurekAlert
Freiburg researchers show how the membrane protein CD20 keeps the immune system’s antibody-producing cells in check.
IMAGE: Freiburg researchers investigate how the membrane protein CD20 organizes the nanostructures on the B cell membrane.
view more
Credit: Illustration: Julia Jullesova
Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University of Freiburg have now solved a mystery about how it works. A team headed by Professor Dr. Michael Reth used cell cultures, healthy cells, and cells from cancer patients…
-
Business16 hours agoThis ASX 200 healthcare stock crashed 14% to 4-year low. Here’s what happened
-
Business20 hours agoThis leading broker thinks the CSL share price can climb 40%
-
Business13 hours agoDicker Data rides the AI trend to double digit growth
-
Noosa News20 hours agoOld Translink app canned, and new version ‘worse than paper map from 2015’